Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study enrolls patients with Non-small cell lung cancer and treats them with the
investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an
antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which,
in turn, may lead to cancer elimination.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio